紫杉醇、奈达铂同步后程加速超分割放疗联合体外高频热疗对局部晚期食管癌的影响

刘丽华++++++蔡君东++++++刘艳琴++++++郑玉妹++++++王海生++++++丁柏英++++++李晓东++++++刘晶++++++乔炜超++++++董新红

[摘要] 目的 探討紫杉醇、奈达铂同步后程加速超分割放疗联合体外高频热疗对局部晚期食管癌的影响。 方法 选取2011年8月～2012年7月承德市肿瘤医院收治的局部晚期食管癌患者144例，采用随机数字表法将其分为对照组（72例）与联合组（72例）。对照组患者应用紫杉醇、奈达铂同步后程加速超分割放疗干预，联合组患者在对照组放疗基础上联合体外高频热疗，对比两组患者治疗效果及生存率情况，观察两组患者毒副作用发生情况。 结果 联合组患者治疗总有效率（86.11%）明显高于对照组（62.50%），差异有统计学意义（P < 0.05）；两组患者治疗期间均存在毒副作用，两组毒副作用发生率差异无统计学意义（P > 0.05）；联合组患者1、2、3、4年生存率（70.83%、55.56%、45.83%、38.89%）明显高于对照组（55.56%、40.27%、29.17%、22.22%），差异有统计学意义（P < 0.05）。 结论 局部晚期食管癌患者应用紫杉醇、奈达铂同步后程加速超分割放疗联合体外高频热疗治疗的效果较好，且生存率高，存在一定推广价值。

[关键词] 奈达铂；紫杉醇；后程加速超分割；体外高频热疗；食管癌

[中图分类号] R735.1 [文献标识码] A [文章编号] 1673-7210（2017）08（b）-0080-04

[Abstract] Objective To explore the influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer. Methods From August 2011 to July 2012， in Chengde Tumour Hospital， 144 patients with locally advanced esophageal cancer were selected， and they were divided into control group （72 cases） and observation group （72 cases） according to the random number table method. The control group was treated with Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy， and the observation group was given ombined with hyperthermia in vitro on the basis of the control group. The rapeutic effect and survival rate in the two groups were contrasted， and toxic and side effects in the two groups were observed. Results The total effective rate of the combination group （86.11%） was significantly higher than that of the control group （62.50%）， the difference was statistically significant （P < 0.05）. The side effects during the treatment occured in two groups， two groups were compared， the difference was not statistically significant （P > 0.05）. Survival rates of 1， 2， 3， 4 years in the observation group （70.83%， 55.56%， 45.83%， 38.89%） were significantly higher than those in the control group （55.56%， 40.27%， 29.17%， 22.22%）， the differences were statistically significant （P < 0.05）. Conclusion The effect is better of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with hyperthermia in vitro on patients with locally advanced esophageal cancer， with high survival rate. It has a certain promotion value.

[Key words] Nedaplatin； Paclitaxel； Accelerated hyperfractionation； Extracorporeal high-frequency hyperthermia； Esophageal cancerendprint